Open Access

Primary bone lymphoma of the left radius: a case report and related literature review

Contributed equally
European Journal of Medical Research201419:19

DOI: 10.1186/2047-783X-19-19

Received: 16 December 2013

Accepted: 31 March 2014

Published: 9 April 2014

Abstract

Primary bone lymphoma (PBL) is a rare but distinct clinicopathological disease. Because it is not common, the optimal treatment strategy has not been established. Here, we present a patient with PBL of the left radius and review the related literature. We focus on the standard treatment for PBL. Many aspects such as rehabilitation, local control and overall survival need to be considered. Studies on this disease should be carried out to clarify the optimal treatment in the future.

Keywords

Bone lymphoma Chemotherapy Radiotherapy

Background

Primary bone lymphoma (PBL) is a distinct disease. Here, we present a patient with PBL who received combined therapy with radiotherapy, chemotherapy, surgery and rituximab. Additionally, related reports of PBL are reviewed. Further studies are needed to establish the standard strategy for PBL.

Case presentation

A 53-year-old man presented at the First Hospital of Jilin University (Changchun, China) in December 2011 with a history of progressive pain of the left wrist for about 2 months. The X-ray radiograph of the left upper extremity showed a large osteolytic lesion of the distal radius (Figure 1). The bone biopsy from another hospital revealed B cell non-Hodgkin lymphoma. The immunochemistry showed: LCA(+), CD20(+), BCL-2(slightly +), CD79a(-), CD3(-), CD43(-), CD56(-), CD138(-), CD38(-), κ(-), λ(-) and Ki-67(70%+). The patient then went to the tertiary hospital for consultation of the pathologic results. The definitive diagnosis was diffuse large B cell lymphoma, derived from active B cells out of the germinal center. The immunochemistry revealed: CD10(-), BCL6(+), MUM-1(+), CD5(-) and cyclin D1(-). Positron emission tomography-computed tomography (PET/CT) suggested that there was extremely intense focal uptake in the distal left radius and no focal uptake in other sites (Figure 2). The patient did not have fever, night sweats, pruritus or weight loss.
https://static-content.springer.com/image/art%3A10.1186%2F2047-783X-19-19/MediaObjects/40001_2013_Article_101_Fig1_HTML.jpg
Figure 1

X-ray radiograph showed a large osteolytic lesion of the distal region of the left radius.

https://static-content.springer.com/image/art%3A10.1186%2F2047-783X-19-19/MediaObjects/40001_2013_Article_101_Fig2_HTML.jpg
Figure 2

Pre-therapeutic PET/CT showed intensive FDG uptake in the distal region of the left radius. FDG, fluorodeoxyglucose; PET/CT, positron emission tomography-computed tomography.

Laboratory investigations demonstrated a normal complete blood cell count and a generally normal serum biochemical profile. β2 microglobulin was 2.30 mg/L. Erythrocyte sedimentation rate was 17 mm/h. Lactate dehydrogenase was normal. The bone marrow aspiration did not find neoplastic involvement. Thus, a primary bone lymphoma, Ann Arbor stage I, International Prognostic Index score 0, was diagnosed.

First, the patient received radiotherapy. When the dose reached 28 Gy/14 f, we gave a cycle of concurrent chemotherapy of rituximab, cyclophosphamide, vincristine and prednisone (R-COP), and the fraction dose was reduced to 1.5 Gy. The total dose was 28 Gy/14 f plus 12 Gy/8 f. The patient then received a cycle of single rituximab. On 1 February 2012, surgery was performed to remove the tumor at the distal region of the left radius, and autograft of the fibula was done and then internally fixed. Thirty radioactive iodines were implanted into the primary tumor bed during the surgery. The post-operative PET-CT did not find any intensive focal uptake. The patient then received a cycle of single rituximab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) and CHOP, respectively. To date, the patient’s condition remains stable and disease-free survival (DFS) has reached nearly 2 years.

Discussion

PBL is a rare but distinct clinicopathological entity. It accounts for approximately 5% of all non-Hodgkin lymphomas and 3% of all primary bone tumors [1]. Because it is not common, many aspects of the diagnosis, management and prognosis of this tumor remain controversial.

PBL occurs in a wide spectrum of patients, aged from 1 year and 6 months to 86 years [2], commonly between 20 and 50 years of age, and is more common in males. Diffuse large B cell lymphoma is the most common pathological type, accounting for about 80% of PBLs [37]. The most frequent sites of involvement in PBL are the vertebra, pelvis, femur, humerus, skull and rib [3]. Common clinical manifestations include local pain and swelling [1].

Ford et al. showed that combined modality treatment (CMT) provided both disease control and survival benefits for PBL compared with single treatment [8]. However, the role of radiotherapy for advanced PBL was challenged in a report by Ramadan et al. [3]. The addition of radiotherapy to chemotherapy for advanced cases reduced the 10-year overall survival from 56% to 25%. Whether CMT should be the standard option for PBL requires more research. Achemlal et al. reported a case in which rituximab resulted in remarkable improvement for a chemo-resistant PBL [9]. Ramadan et al. insisted that irradiation should be carried out when spinal cord compression or residual tumor after chemotherapy existed, which seemed that irradiation only played a minor role [3]. On the contrary, a prospective trial emphasized the importance of radiotherapy to improve the local control and recommended a higher dose (40 to 45 Gy) than that for other types of lymphoma [10]. A retrospective, multicenter Rare Cancer Network (RCN) study also presented a good outcome offered by chemoradiotherapy for early stage of PBL [11]. For a case of PBL of the left mandible, Bosch-Barrera et al. reported that chemotherapy (R-CHOP) plus consolidate radiotherapy can result in tumor-free survival of 28 months [12].

Orthopedic intervention is usually needed for pathologic fractures, avascular necrosis, spinal cord compression, or for lesions of the weight-bearing bones compromising stability or joint motion. The potential for long-term survival suggests the use of implants and techniques that have the best chance of long-term control [13]. In our case, concurrent radiotherapy and chemotherapy were given to rapidly eliminate the tumor. However, pathological fracture did happen and we had to remove the tumor surgically. Autograft of the fibula was done and then internally fixed.

PBL has a favorable prognosis over patients of systemic lymphoma with bone involvement. Age is a prognostic factor. The majority of the reports indicate better survival for patients younger than 60 years, but there are a few other reports that show better survival in patients younger than 40 or 50 years [4]. Jawad et al. analyzed 1,500 adult patients with PBL, and pointed out that younger age and localized disease were independent predictors of survival [14]. The study also noted that the incidence of the disease has increased during recent years [14]. Future treatment for patients with PBL needs to be dependent on strict staging criteria and adherence to successful published protocols using collaborative clinical trials.

Conclusion

PBL is a rare but distinct clinicopathological entity. Compared with single treatment, CMT can result in both a good local control rate and survival benefits for local PBL.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Authors’ information

ML and BL are the joint first authors.

Notes

Abbreviations

CMT: 

Combined modality treatment

DFS: 

Disease-free survival

FDG: 

Fluorodeoxyglucose

PBL: 

Primary bone lymphoma

R-COP: 

Rituximab, cyclophosphamide, vincristine, prednisone

R-CHOP: 

Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.

Declarations

Acknowledgements

The authors thank Guangnan Chen for revision of the medical English in the article.

Authors’ Affiliations

(1)
Department of Radiation Oncology, The First Hospital, Jilin University
(2)
Cancer Center, The First Hospital, Jilin University

References

  1. Limb D, Dreghorn C, Murphy JK, Mannion R: Primary lymphoma of bone. Int Orthop 1994, 18: 180–183.PubMedView ArticleGoogle Scholar
  2. Huebner-Chan D, Fernandes B, Yang G, Lim MS: An immunophenotypic and molecular study of primary large B-cell lymphoma of bone. Mod Pathol 2001, 14: 1000–1007. 10.1038/modpathol.3880425PubMedView ArticleGoogle Scholar
  3. Ramadan KM, Shenkier T, Sehn LH, Gascoyne RD, Connors JM: A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Ann Oncol 2007, 18: 129–135.PubMedView ArticleGoogle Scholar
  4. Beal K, Allen L, Yahalom J: Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer 2006, 106: 2652–2656. 10.1002/cncr.21930PubMedView ArticleGoogle Scholar
  5. de Camargo OP, dos Santos Machado TM, Croci AT, de Oliveira CR, Giannotti MA, Baptista AM, Caiero MT, Alves VA, Matsumoto LA: Primary bone lymphoma in 24 patients treated between 1955 and 1999. Clin Orthop Relat Res 2002, 397: 271–280.PubMedView ArticleGoogle Scholar
  6. Horsman JM, Thomas J, Hough R, Hancock BW: Primary bone lymphoma: a retrospective analysis. Int J Oncol 2006, 6: 1571–1575.Google Scholar
  7. Zinzani PL, Carrillo G, Ascani S, Barbieri E, Tani M, Paulli M, Stefoni V, Sabattini E, Alinari L, Binazzi R, Tura S, Baccarani M, Pileri SA: Primary bone lymphoma: experience with 52 patients. Haematologica 2003, 3: 280–285.Google Scholar
  8. Ford DR, Wilson D, Sothi S, Grimer R, Spooner D: Primary bone lymphoma: treatment and outcome. Clin Oncol 2007, 19: 50–55. 10.1016/j.clon.2006.10.007View ArticleGoogle Scholar
  9. Achemlal L, Mikdame M, Nouijai A, Bezza A, El Maghraoui A: Dramatical improvement of chemoresistant bone lymphoma with rituximab. Clin Rheumatol 2006, 25: 394–395. 10.1007/s10067-005-0060-xPubMedView ArticleGoogle Scholar
  10. Christie D, Dear K, Le T, Barton M, Wirth A, Porter D, Roos D, Pratt G: Limited chemotherapy and shrinking field radiotherapy for osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trial. Int J Radiat Oncol Biol Phys 2011, 80: 1164–1170. 10.1016/j.ijrobp.2010.03.036PubMedView ArticleGoogle Scholar
  11. Cai L, Stauder MC, Zhang YJ, Poortmans P, Li YX, Constantinou N, Thariat J, Kadish SP, Nguyen TD, Kirova YM, Ghadjar P, Weber DC, Bertran VT, Ozsahin M, Mirimanoff RO: Early-stage primary bone lymphoma: a retrospective, multicenter Rare Cancer Network (RCN) study. Int J Radiat Oncol Biol Phys 2012, 83: 284–291. 10.1016/j.ijrobp.2011.06.1976PubMedView ArticleGoogle Scholar
  12. Bosch-Barrera J, Arbea L, García-Velloso MJ, Gil-Bazo I, García-Foncillas J, Panizo C: Primary bone lymphoma of the mandible and thyroid incidentaloma identified by 18FDG PET/CT: a case report. Cases J 2009, 2: 6384.PubMedPubMed CentralGoogle Scholar
  13. Demircay E, Hornicek FJ Jr, Mankin HJ, Degroot H 3rd: Malignant lymphoma of bone: a review of 119 patients. Clin Orthop Relat Res 2013, 471: 2684–2690. 10.1007/s11999-013-2991-xPubMedPubMed CentralView ArticleGoogle Scholar
  14. Jawad MU, Schneiderbauer MM, Min ES, Cheung MC, Koniaris LG, Scully SP: Primary lymphoma of bone in adult patients. Cancer 2010, 116: 871–879. 10.1002/cncr.24828PubMedView ArticleGoogle Scholar

Copyright

© Liu et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.